Faculty Profile: Patricia Dickson, M.D.

Assistant Professor

Certifications:

American Board of Pediatrics, 2002
American Board of Medical Genetics, 2006

Experience and Professional Training:

1999-2002 Internship and Residency, Pediatrics, Los Angeles County/Harbor-UCLA Medical Center, Torrance, CA
2002-2003 Chief Residency, Pediatrics, Los Angeles County/Harbor-UCLA Medical Center, Torrance, CA
2003-2006 Fellowship, UCLA Intercampus Medical Genetics Training Program, Los Angeles, CA
2005-2006 Clinical Instructor, David Geffen School of Medicine at UCLA, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA
2006- Assistant Professor, David Geffen School of Medicine at UCLA,
2007-2009 Associate Faculty, UCLA Intercampus Medical Genetics Training Program, Los Angeles, CA
2009- Faculty, UCLA Intercampus Medical Genetics Training Program, Los Angeles, CA

Contact Information:

Phone: (310) 222-3756
Fax: (310) 328-9921
Email: pdickson@ucla.edu

Research Focus:

The MPS research lab focuses on finding treatments for the brain in the mucopolysaccharidoses. The mucopolysaccharidoses (MPS) are a group of rare genetic diseases. Current projects include intrathecal enzyme replacement therapy for mucopolysaccharidosis type I, immune tolerance to enzyme replacement, and developing enzyme replacement therapy for mucopolysaccharidosis type III.

Selected Publications:

1. Dayan P, Ahmad F, Urtecho J, Novick M, Dixon P (sic), Levine D, Miller S. Test characteristics of the respiratory syncytial virus enzyme-linked immunoabsorbent assay in febrile infants < or = 60 days of age. Clinics in Pediatrics 41:415-8, 2002.

2. Joyce JJ, Dickson PI, Qi N, Noble JE, Raj JU, Baylen BG. Normal right and left ventricular mass development during early infancy. American Journal of Cardiology 93:797-801, 2004.

3. Dickson PI, Briones N, Baylen BG, Jonas AJ, French SW, Lin HJ. Costello syndrome with pancreatic islet cell hyperplasia: comparison to disorders of insulin or insulin-like growth factor pathways. American Journal of Medical Genetics Part A, 130:402-405, 2004.

4. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Molecular Genetics and Metabolism, 83:163-174, 2004.

5. Belichenko PV, Dickson P, Passage M, Jungles S, Mobley WC, Kakkis E. Penetration, diffusion and uptake of recombinant human α-L-iduronidase after intraventricular injection into the rat brain. Molec Genet Metab 86:141-149, 2005.

6. Tiranti V, Briem E, Lamantea E, Mineri R, Papaleo E, Degioia L, Forlani F, Rinaldo P, Dickson P, Abu-Libdeh B, Cindro-Heberle L, Owaidha M, Jack RM, Christensen E, Burlina A, Zeviani M. ETHE1 mutations are specific to Ethylmalonic Encephalopathy. J Med Genet. 43:340-6, 2006.

7. Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M, Hanson S, Passage M, Kakkis E. Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Molec Genet Metab 91:61-68, 2007.

8. Dickson P, Peinovich M, McEntee M, Lester T, Le S, Krieger A, Manuel H, Jabagat C, Passage M, Kakkis E. Immune tolerance improves the efficacy of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. J Clin Invest, 118:2868-76, 2008.

9. Muñoz-Rojas MV, Costa R, Fagondes Canani S, Jardim L, Vedolin L, Kakkis E, Dickson P, Vieira T, John AB, Raymundo M, Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet, 146A:2538-44, 2008.

10. Passage MB, Krieger AW, Peinovich MC, Lester T, Le SQ, Dickson PI (corresp), Kakkis, ED. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs. J Inh Metab Dis, epub June 28, 2009.

11. Carlstrom LP, Jens JK, Dobyns ME, Passage M, Dickson PI, Ellinwood NM. Canine factor VII deficiency: Propagation of inadvertent inherited genetic disease within a canine mucopolysaccharidosis type I research breeding colony. Comp Med, 59: 378-382, 2009.

12. Dickson, PI. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol; 47 (Suppl 1): S124–S127, 2009.